The Health Sciences Institute is intended to provide cutting-edge health information.
Nothing on this site should be interpreted as personal medical advice. Always consult with your doctor before changing anything related to your healthcare.

Russian Roulette with off-label drug: Long-term health risks

Coming Up Short

Imagine you have a 15-year-old son who wants to play Russian roulette. Would you let him play?

Absurd question, isn’t it? Here’s an even more absurd scenari Imagine your son has no opinion one way or another about playing Russian roulette. Nevertheless, you load the gun and hand it to him.

I know. It sounds crazy. But that metaphor fits a recent study that encourages the off-label use of a drug that could easily put young men in jeopardy of long-term health risks. And when you find out what the desired outcome is, you might wonder how in the world the researchers enlisted parents who were willing to let their children enroll in a study that couldn’t possibly promise a 100 percent safe outcome.

——————————————–
Tall, dark and handsome
——————————————–

Tall men have it good. According to the web site for the Baltimore Tall Club, “Studies have shown that tall men make more money, are more likely to win an election and have an easier time dating.”

Well, as Sigmund Freud famously pointed out: Anatomy is destiny.

But Freud, you know, he’s just so 20th Century. Here in the 21st we have the means to tinker with both anatomy and destiny.

The December 2005 issue of the journal Pediatrics includes a study conducted at the Riley Hospital for Children, Indiana University School of Medicine. Seven short teenage boys (their average age was about 15) were given tamoxifen two times each day. Intervention periods ranged from six months to four years. Researchers report that the boys’ predicted adult height increased by almost four inches.

Couple of things: 1) Did you catch the word “predicted”? As the researchers note, additional evaluation will be required to assess whether or not the boys will actually turn out to be taller than expected. And 2) Six of the boys were also taking growth hormones during the testing period.

And one more thing: tamoxifen. Ring a bell? In the e-Alert “The Road Less Traveled” (12/21/05) I told you about this synthetic hormone-like drug. It’s used to treat estrogen-driven breast cancers by preventing estrogen from binding to breast cancer cells. Needless to say, increasing the height of boys of modest stature is an “off-label” use of tamoxifen. WAY off-label.

——————————————–
Further on up the road
——————————————–

This was not a long-term study, so the extended effects of tamoxifen combined with a growth hormone won’t be known unless someone follows up on this research in years to come. Meanwhile, the researchers claim that tamoxifen was used “without negative effects on sexual maturation.”

Really? How could they possibly come to this breezy conclusion without following the boys’ progress for a decade or more?

Here’s what I wrote about tamoxifen in last month’s e-Alert: “The most common side effects are not life threatening, but according to breastcancer.org ‘they may still decrease your quality of life, sometimes to a considerable degree.’ That’s because tamoxifen can prompt hot flashes, nausea, vomiting, weight gain, mood swings, depression and a loss of energy. And those are only the annoying side effects. The dangerous side effects include an increased risk of developing blood clots as well as uterine and liver cancers.”

It’s safe to say that the boys – whatever their adult height turns out to be – won’t experience hot flashes or uterine cancer. But it astonishes me that researchers and parents would consider a few “predicted” extra inches of height worth the risk of potentially life-threatening health problems.

I guess I shouldn’t be astonished at anything like this anymore. After all, one of the bombshells of the recent Vioxx scandal involved children, although most people never heard about this deplorable detail as the larger scandal unfolded.

When Merck pulled the plug on Vioxx in the fall of 2004, we found out that the FDA had known for years that the drug was associated with an increased risk of heart attack and stroke. And as unsettling as that is, that’s not the bombshell. This is the bombshell: In early September of 2004, the FDA approved the use of Vioxx for kids. And according to WebMD Medical News, this approval was based on a trial that lasted only three months. Not exactly what you’d call a “long-term” study.

So we shouldn’t be astonished that the medical community is comfortable about putting kids at risk as research guinea pigs. Outraged? Yes. Astonished? No.

****************************************************

and another thing

Sometimes what you’re looking for is right under your nose.

After I sent you yesterday’s e-Alert with some comments about the sorry state of U.S. health care, a colleague (and e-Alert reader) called to tell me about a doctor she’s working with who – no kidding – actually takes the time to listen to his patients.

His name is Alan Inglis, M.D., but he’s better known as America’s Country Doctor. According to Dr. Inglis, physicians interrupt their patients after an average of only 18 seconds! Then they end up spending just minutes with each patient. That’s an ideal way to sell drugs and manage a double-booked schedule, but there’s usually not much “care” in that concept of health care.

After spending years actually listening to his patients, Dr. Inglis has developed a medical practice that offers a highly effective and practical mix of alternative and conventional treatments. And what’s more, he’s also quite knowledgeable about nutrition. We’ve heard that his patients seem very pleasantly surprised when he tells them they’re eating wrong and then pulls out his 10 ways that chocolate is better for you than broccoli or prunes! For more information go to: http://www.americascountrydoctor.com

To Your Good Health,

Jenny Thompson

Tap into the minds of other health-conscious readers like yourself at the new HSI health forum: http://www.healthiertalk.com

Sources:

“The Use of Tamoxifen to Improve Height Potential in Short Pubertal Boys” Pediatrics, Vol. 116, No. 6, December 2005, pediatrics.aappublications.org
“Tamoxifen May Boost Short Boys’ Height” Miranda Hitti, WebMD Medical News, 12/13/05, webmd.com
“Cancer Drug may Help Short Boys be Taller” Reuters, 12/8/05, msnbc.msn.com

Get a free copy of 5 Household Items that Cause Cancer

By texting HSI to 844-539-1128, you are providing your electronic signature expressly consenting to be called and texted (including by prerecorded messages, using an autodialer, and/or automated means) with alerts, stories, reports, and marketing communications from Institute of Health Sciences, LLC. and its authorized representatives at the phone number you provide, including landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also consent and unconditionally agree to our Privacy Policy and Terms of Use, including the arbitration provision and class action waiver contained therein. Msg&data rates may apply. 15 Msgs/Month. You are not required to agree to this as a condition of making a purchase.

Terms & Conditions

The following Terms and Conditions apply to your use of the website located at hsionline.com (the “website”) and any text messages that you send to or receive from the Institute of Health Sciences, L.L.C. These Terms and Conditions constitute a binding agreement (“Agreement”) between you (“you”) Institute of Health Sciences, L.L.C (“we”, “us”, etc.)  Please read these terms carefully. 

By providing your telephone number to us, texting us a short code listed on the website, or otherwise indicate your agreement to these Terms and Conditions, you are agreeing to the mandatory arbitration provision and class action waiver below. 

ARBITRATION IS MANDATORY AND THE EXCLUSIVE REMEDY FOR ANY AND ALL DISPUTES RELATED TO THIS WEBSITE, THIS AGREEMENT, AND ANY TELEPHONE CALLS, EMAILS, OR TEXT MESSAGES THAT YOU RECEIVE FROM OR ON BEHALF OF US, UNLESS SPECIFIED BELOW OR UNLESS YOU OPT-OUT.

Text Messaging and Telemarketing Terms and Conditions

When you provide your telephone number on this website or send a text message to us with or from a short-code, you agree to receive alerts and communications, and marketing messages including those sent via automated telephone dialing system, text messages, SMS, MMS, and picture messages from Institute of Health Sciences, L.L.C at the phone number you provide on this website or the phone number from which you text the short code, including on landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also agree to the mandatory arbitration provision and class action waiver below. Your consent is not required to purchase goods or services. Message & data rates may apply.

You may opt-out at any time by texting the word STOP to the telephone number from which you receive the text messages.  Call 1-888-213-0764 to learn more.  By providing your telephone number, you agree to notify us of any changes to your telephone number and update your account us to reflect this change. Your carrier may charge you for text messages and telephone calls that you receive, or may prohibit or restrict certain mobile features, and certain mobile features may be incompatible with your carrier or mobile device. Contact your carrier with questions regarding these issues.

Dispute Resolution by Binding Arbitration and Class Action Waiver

Any dispute relating in any way to telephone calls, emails, or text messages that you receive from or on behalf of Institute of Health Sciences, L.L.C this website, or this Agreement (collectively “Disputes”) shall be submitted to confidential arbitration and shall be governed exclusively by the laws of the State of Maryland, excluding its conflict of law provisions.  For the avoidance of doubt, all claims arising under the Telephone Consumer Protection Act and state telemarketing laws shall be considered “Disputes” that are subject to resolution by binding individual, confidential arbitration.

If a Dispute arises under this Agreement, you agree to first contact us at 1-888-213-0764 or help@hsionline.com. Before formally submitting a Dispute to arbitration, you and we may choose to informally resolve the Dispute.  If any Dispute cannot be resolved informally, you agree that any and all Disputes, including the validity of this arbitration clause and class action waiver, shall be submitted to final and binding arbitration before a single arbitrator of the American Arbitration Association (“AAA”) in a location convenient to you or telephonically. Either you or we may commence the arbitration process by submitting a written demand for arbitration with the AAA, and providing a copy to the other party.  The arbitration will be conducted in accordance with the provisions of the AAA’s Commercial Dispute Resolutions Procedures, Supplementary Procedures for Consumer-Related Disputes, in effect at the time of submission of the demand for arbitration.  Except as may be required by law as determined by the arbitrator, no party or arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties. Institute of Health Sciences, L.L.C will pay all of the filing costs.  Without limiting the foregoing, YOU EXPRESSLY AGREE TO SUBMIT TO ARBITRATION ALL DISPUTES RELATING TO ANY TEXT MESSAGES OR TELEPHONE CALLS YOU RECEIVE FROM OR ON BEHALF OF US OR ANY ENTITY WITH WHOM WE MAY SHARE YOUR TELEPHONE NUMBER.  Further, we both agree that all entities with whom we share your telephone numbers shall be third party beneficiaries of this Agreement to Arbitrate Disputes, and that those entities have the same rights as Institute of Health Sciences, L.L.C to enforce this arbitration provision.

Notwithstanding the foregoing, the following shall not be subject to arbitration and may be adjudicated only in the state and federal courts of Maryland: (i) any dispute, controversy, or claim relating to or contesting the validity of our or one of our family company’s intellectual property rights and proprietary rights, including without limitation, patents, trademarks, service marks, copyrights, or trade secrets; (ii) an action by us for temporary or preliminary injunctive relief, whether prohibitive or mandatory, or other provisional relief; (iii) any legal action by us against a non-consumer; or (iv) interactions with governmental and regulatory authorities.  You expressly agree to refrain from bringing or joining any claims in any representative or class-wide capacity, including but not limited to bringing or joining any claims in any class action or any class-wide arbitration.

The arbitrator’s award shall be binding and may be entered as a judgment in any court of competent jurisdiction. To the fullest extent permitted by applicable law, no arbitration under this Agreement may be joined to an arbitration involving any other party subject to this Agreement, whether through a class action, private attorney general proceeding, class arbitration proceedings or otherwise.

YOU UNDERSTAND THAT YOU WOULD HAVE HAD A RIGHT TO LITIGATE IN A COURT, TO HAVE A JUDGE OR JURY DECIDE YOUR CASE AND TO BE PARTY TO A CLASS OR REPRESENTATIVE ACTION.  HOWEVER, YOU UNDERSTAND AND AGREE TO HAVE ANY CLAIMS DECIDED INDIVIDUALLY AND ONLY THROUGH ARBITRATION.  You shall have thirty (30) days from the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, to opt out of this arbitration agreement, by contacting us by email at help@hsionline.com or by mail Health Sciences Institute, PO Box 913, Frederick, MD 21705-0913. If you do not opt out by the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, then you are not eligible to opt out of this arbitration agreement.

Electronic Signatures

All information communicated on the website is considered an electronic communication.  When you communicate with us through or on the website, by text message or telephone, or via other forms of electronic media, such as e-mail, you are communicating with us electronically.  You agree that we may communicate electronically with you and that such communications, as well as notices, disclosures, agreements, and other communications that we provide to you electronically, are equivalent to communications in writing and shall have the same force and effect as if they were in writing and signed by the party sending the communication.

You further acknowledge and agree that by clicking on a button labeled “ORDER NOW”, “SUBMIT”, “I ACCEPT”, “I AGREE”, “YES”, by texting a short code to us in response to a request on this website, or by clicking or similar links or buttons, you are submitting a legally binding electronic signature and are entering into a legally binding contract.  You acknowledge that your electronic submissions constitute your agreement and intent to be bound by this Agreement.  Pursuant to any applicable statutes, regulations, rules, ordinances or other laws, including without limitation the United States Electronic Signatures in Global and National Commerce Act, P.L. 106-229 (the “E-Sign Act”) or other similar statutes, YOU HEREBY AGREE TO THE USE OF ELECTRONIC SIGNATURES, CONTRACTS, ORDERS AND OTHER RECORDS AND TO ELECTRONIC DELIVERY OF NOTICES, POLICIES AND RECORDS OF TRANSACTIONS INITIATED OR COMPLETED THROUGH THE WEBSITE.  Furthermore, you hereby waive any rights or requirements under any statutes, regulations, rules, ordinances or other laws in any jurisdiction which require an original signature, delivery or retention of non-electronic records, or to payments or the granting of credits by other than electronic means You may receive a physical paper copy of this contract by contacting us at help@hsionline.com.

Privacy Policy

Please read our Privacy Policy, which is incorporated herein by reference.  In the event of any conflict between these Terms and Conditions and the Privacy Policy, these Terms shall control.

Contact Us

You may contact us by telephone at 1-888-213-0764 or by email at help@hsionline.com.